JPMorgan Chase & Co. Buys 215,995 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

JPMorgan Chase & Co. lifted its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 265.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 297,367 shares of the company's stock after acquiring an additional 215,995 shares during the period. JPMorgan Chase & Co. owned approximately 0.20% of MiMedx Group worth $1,757,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Blue Trust Inc. acquired a new position in MiMedx Group during the third quarter worth $30,000. Point72 Asset Management L.P. bought a new stake in MiMedx Group during the 2nd quarter worth approximately $40,000. Point72 DIFC Ltd increased its holdings in MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after purchasing an additional 4,275 shares in the last quarter. Entropy Technologies LP bought a new position in shares of MiMedx Group in the third quarter valued at about $64,000. Finally, Orion Capital Management LLC lifted its position in MiMedx Group by 46.3% during the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company's stock worth $69,000 after buying an additional 3,700 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Trading Up 0.4 %

MDXG stock traded up $0.04 during midday trading on Thursday, reaching $9.03. The stock had a trading volume of 464,085 shares, compared to its average volume of 618,068. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of 16.42 and a beta of 1.96. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The business has a fifty day simple moving average of $9.22 and a two-hundred day simple moving average of $7.44.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.02. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $84.06 million during the quarter, compared to the consensus estimate of $81.00 million. During the same period in the previous year, the firm posted $0.05 earnings per share. As a group, research analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.